Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2019-08-16

Original market date: See footnote 1

1998-08-14

Product name:

AMPICILLIN FOR INJECTION, USP

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02227029

Product Monograph/Veterinary Labelling:

Date: 2019-08-16 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

FRESENIUS KABI CANADA LTD
165 Galaxy Blvd, Suite 100
Toronto
Ontario
Canada M9W 0C8

Class:

Human

Dosage form(s):

Powder For Solution

Route(s) of administration:

Intramuscular ,  Intravenous

Number of active ingredient(s):

1

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

08:12.16.08 

Anatomical Therapeutic Chemical (ATC): See footnote 4

J01CA01 AMPICILLIN

Active ingredient group (AIG) number:See footnote5

0105872002

List of active ingredient(s)
Active ingredient(s) Strength
AMPICILLIN (AMPICILLIN SODIUM) 250 MG / VIAL
Version 4.0.2
Date modified: